Bristol-Myers sees 'encouraging' trends for Eliquis with hopes of expansion Expects to have data from third line Phase II study in squamous non-small cell lung cancer in first part of 2014. It will also continue to explore combinations as well as initiating first line Phase III monotherapy study. Bristol-Myers said assets in the U.S. are in a much better position entering 2014 for both commercial and Medicare Part D plans. Total commercial costs in 2014 are expected to increase from 2013 due to the diabetes transaction. Comments taken from Q4 earnings conference call.
News For BMY From The Last 14 Days
Check below for free stories on BMY the last two weeks.